

# Regulatory Story

[Go to market news section](#)



**Cathay International Holdings Ld** - CTI Increase in shareholder loan  
Released 09:19 27-Dec-2019

RNS Number : 1178Y  
Cathay International Holdings Ld  
27 December 2019

**27 December 2019**

## **Cathay International Holdings Limited**

**("Cathay" or the "Company")**

### **Increase in shareholder loan**

Reference is made to the Company's announcement on 22 November 2019 relating to the USD23 million loan facility (the "Loan Facility") from Cathay International EW No. 43 Limited ("CIEW43"), a company controlled by Mr. Wu, the Chairman of the Company.

The Company announces that it has further agreed with CIEW43 today to increase the Loan Facility by USD11 million to USD34 million for the Group's working capital. As disclose in the previous announcement, the Loan Facility is on normal commercial terms, has an initial term of 1 year, interest is payable at the rate of LIBOR +3.5% per annum and is unsecured. In addition, the loan is repayable in certain events of default or in the event that the Company raises capital through the sale of assets or otherwise.

**- ENDS -**

**For further enquiries, please contact:**

**Cathay International Holdings Limited**

Eric Siu (Finance Director)

Tel: +852 2828 9289

Patrick Sung (Director and Controller)

**Consilium Strategic Communications**

Mary-Jane Elliott / Matthew Neal / Tel: +44 (0) 203 709 5702

Lindsey Neville

**About Cathay**

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: [www.cathay-intl.com.hk](http://www.cathay-intl.com.hk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

MSCKDLBLKLFBBE

CLOSE

---

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. **Terms and conditions**, including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

Increase in shareholder loan - RNS